Organogenesis Holdings Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | — |
| Cost of revenue | — | $115.7M | $106.5M | $105.0M | — |
| Gross profit | — | $366.3M | $326.7M | $345.9M | — |
| Selling, general & administrative | $326.2M | $294.5M | $269.8M | $283.8M | — |
| Research and development | $44.5M | $50.3M | $44.4M | $39.8M | — |
| Operating expenses | $519.5M | $483.3M | $420.6M | $323.6M | — |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | — |
| Interest expense | $2.3M | $1.5M | $2.2M | $2.0M | — |
| Pretax income | $47.0M | -$2.8M | $10.4M | $20.3M | — |
| Income tax expense | $9.9M | -$3.7M | $5.4M | $4.8M | — |
| Net income | $37.0M | $861,000 | $4.9M | $15.5M | — |
| Balance Sheet | |||||
| Cash and equivalents | $93.7M | $135.6M | $103.8M | $102.5M | — |
| Current assets | $362.2M | $285.9M | $225.0M | $222.6M | — |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | — |
| Current liabilities | $100.1M | $77.5M | $80.5M | $75.0M | $78.5M |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $194.7M |
| Stockholders' equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.3M | $14.2M | $30.9M | $24.9M | — |
| Depreciation and amortization | $15.3M | $13.6M | $10.4M | $5.8M | — |
| Stock-based compensation | $13.3M | $10.6M | $9.0M | $6.6M | — |
| Capital expenditure | $14.2M | $10.0M | $24.4M | $33.9M | — |
| Free cash flow | -$24.5M | $4.2M | $6.6M | -$9.0M | — |
| Share repurchases | — | $25.5M | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 128.7M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.